Repeat -- quoin pharmaceuticals announces additional positive clinical data from open-label, single-arm clinical trial in netherton syndrome

Available clinical data from six subjects demonstrates well defined efficacy signals across a number of study endpoints

QNRX Ratings Summary

QNRX Quant Ranking